Bayer says Nexavar misses target in liver cancer trial

FRANKFURT (Reuters) - Germany's Bayer said a Phase III trial of cancer drug Nexavar as an adjuvant therapy for liver cancer did not meet its main target.

via Reuters: Health News Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://ift.tt/1kdCzws